The American Journal of Managed Care

What Would Make Therapy Last? How About 2 Targets Each on B Cells and T Cells?

The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...
The American Journal of Managed Care

Study Identifies Key Predictors of Successful CD3+ Cell Apheresis for CAR T Manufacturing in DLBCL

Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
Business Wire

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer ...
Nasdaq

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...
ascopubs.org

Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the ...

Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer Tumor tissue from 868 patients in the QUASAR ...